Company news
Valeo Pharma Inc. (OTC:VPHIF) news
Valeo Pharma Inc. news releases on 6ix. Latest, Sep 12, 2024: VALEO PHARMA REPORTS THIRD QUARTER 2024 REVENUES
Press releases & updates
VALEO PHARMA REPORTS THIRD QUARTER 2024 REVENUES
September 11, 2024
VALEO PHARMA TO HOST THIRD QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
September 8, 2024
VALEO PHARMA AMENDS CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
September 2, 2024
VALEO PHARMA ANNOUNCES VOLUNTARY DELISTING FROM OTCQB VENTURE MARKET
August 28, 2024
VALEO PHARMA ANNOUNCES LEADERSHIP CHANGES
August 5, 2024
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE
June 17, 2024
VALEO PHARMA REPORTS RECORD SECOND QUARTER 2024 REVENUES
June 12, 2024
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY
June 12, 2024
VALEO PHARMA TO HOST SECOND QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
June 3, 2024
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
April 24, 2024
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
April 8, 2024
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS
March 21, 2024
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS
March 13, 2024
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
March 6, 2024
VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES
February 12, 2024
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
February 1, 2024
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023
January 28, 2024
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCAST
January 21, 2024
VALEO PHARMA ANNOUNCES ORGANIZATIONAL CHANGES AND COST REDUCTION INITIATIVES
November 19, 2023
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. RICHARD LAJOIE TO BOARD OF DIRECTORS
November 6, 2023
VALEO PHARMA MAKES THE LIST OF THE GLOBE AND MAIL'S FIFTH-ANNUAL RANKING OF CANADA'S TOP GROWING COMPANIES
October 3, 2023
VALEO PHARMA ENTERS INTO $5 MILLION CREDIT FACILITY AGREEMENT WITH ACCORD FINANCIAL INC.
September 26, 2023
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES
September 12, 2023
VALEO PHARMA TO HOST THIRD QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
September 6, 2023
VALEO PHARMA CLOSES $4.5 MILLION FINANCING
August 30, 2023
VALEO PHARMA PROVIDES UPDATE ON OPHTHALMOLOGY BUSINESS UNIT
July 3, 2023
VALEO PHARMA ANNOUNCES NEW BOARD APPOINTMENTS
June 21, 2023
VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES
June 12, 2023
VALEO PHARMA TO HOST SECOND QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
June 6, 2023
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023
May 24, 2023
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS
April 27, 2023
VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
April 18, 2023
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023
March 14, 2023
Watch the Valeo Pharma Inc Presentation at the March 9, 2023 Life Sciences Investor Forum
March 10, 2023
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
March 9, 2023
VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
March 8, 2023
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
March 6, 2023
Valeo Pharma to Webcast Live at VirtualInvestorConferences.com March 9th
March 5, 2023
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC
February 7, 2023
VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022
January 30, 2023
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS
January 26, 2023
VALEO PHARMA ANNOUNCES SENIOR MANAGEMENT CHANGE
November 21, 2022
VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE
November 15, 2022
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
September 14, 2022
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2022 RESULTS AND HIGHLIGHTS
September 13, 2022
VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST
September 9, 2022
VALEO PHARMA ADDS PHARMACEUTICAL INDUSTRY VETERAN KYLE STEIGER TO LEADERSHIP TEAM
August 30, 2022
VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS
August 2, 2022
VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT®
August 2, 2022
VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC PRODUCTS, PrXIIDRA® AND PrSIMBRINZA®, IN CANADA
August 2, 2022